AstraZeneca Gets US FDA Approval for Tagrisso for Lung Cancer

AstraZeneca Pharmaceuticals got US FDA approval for Tagrisso (osimertinib) for some adult patients with locally advanced, unresectable non-small cell lung cancer, the agency said on its website.

• Approval covers stage III patients whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations
• Application was granted priority review and breakthrough designation

To view the source of this information, click here

To contact the reporter on this story:
Greg Chang in San Francisco at gchang1@bloomberg.net

To contact the editor responsible for this story:
Zachary Fleming ...